This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)-1β, in post-COVID-19 patients compared with pre-pandemic healthy controls, using data from the Psychiatric Symptoms for COVID-19 Registry Japan (PSCORE-J).<h4>Methods</h4>Blood samples were analyzed from 119 post-COVID-19 patients (median age 45 years) recruited during 2023 and 374 pre-pandemic healthy controls (median age 65 years). The gene discussed is IL1B; the disease is COVID-19.